Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: a meta-analysis.

Abstract

AIM:

This meta-analysis aimed to document the impact of primary tumor site on anti-EGFR monoclonal antibody (mAb) benefit in metastatic colorectal cancer.

MATERIALS & METHODS:

Tumors with metastatic left-sided colorectal cancer (LCC) were compared with tumors with metastatic right-sided colon cancer (RCC) with respect to anti-EGFR mAb objective response rate (ORR), overall survival (OS) and progression-free survival (PFS) benefit.

RESULTS:

Comparing LCC with RCC, LCC was found to have significantly superior anti-EGFR mAb ORR (p < 0.00001), OS (p < 0.00001) and PFS (p < 0.00001) benefit. Additionally, anti-EGFR mAb therapy significantly improved both OS and PFS for LCC compared with no anti-EGFR mAb therapy, but not for RCC. The test of interaction was also apparent for OS (p = 0.0002) and PFS (p = 0.0002).

CONCLUSION:

This meta-analysis demonstrated that LCC had markedly superior anti-EGFR mAb treatment benefit compared with RCC.

• Authors: Dandan Li, Qiang Fu, Man Li, Jun Li, Can Yin, Jin Zhao, Feng Li
• Journal: Future oncology (London, England) (Future Oncol) Vol. 13 Issue 12 Pg. 1115-1127 (May 2017) ISSN: 1744-8301 [Electronic] England
• PMID: 28110551 (Publication Type: Journal Article, Meta-Analysis, Review)

Chemical References

• Antibodies, Monoclonal
• Antineoplastic Agents
• Biomarkers, Tumor
• ErbB Receptors

Topics

• Antibodies, Monoclonal (therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Biomarkers, Tumor
• Colorectal Neoplasms (drug therapy, metabolism, mortality, pathology)
• ErbB Receptors (antagonists & inhibitors, metabolism)
• Humans
• Molecular Targeted Therapy
• Neoplasm Metastasis
• Neoplasm Staging
• Prognosis
• Proportional Hazards Models
• Treatment Outcome